Abstract
The mucosal surfaces of the respiratory, gastrointestinal, and genitourinary tract are entry points for a variety of pathogens and they serve as the first line of defense against infection. To prevent transmission of mucosal pathogens, it is often necessary to target the vaccine to the mucosal surface. Viral vectors, such as poxviruses expressing gene inserts, capable of overcoming the formidable array of host defenses at the mucosal surfaces, are an attractive vaccination strategy for mucosal immunization against infectious diseases. Replication-competent vectors, such as vaccinia, are highly effective, but have a number of safety concerns that may limit their widespread use in humans. In contrast, replication-deficient vectors, such as modified vaccinia ankara (MVA), ALVAC, and NYVAC, may be safer vectors than live vectors, but these vectors may not be as effective at inducing immune responses. Co-delivery of viral vectors with genetic adjuvants (cytokines) or deletion of certain immunomodulatory genomic sequences from these viral vectors may increase vaccine efficiency and are promising strategies for a new generation of mucosal vaccines.
Keywords: Poxviruses, mucosal vaccines, viral vectors, replication-competent, replication-deficient
Current Pharmaceutical Design
Title: Mucosal Vaccine Vectors: Replication-Competent Versus Replication-Deficient Poxviruses
Volume: 13 Issue: 19
Author(s): Lukena U. Karkhanis and Ted M. Ross
Affiliation:
Keywords: Poxviruses, mucosal vaccines, viral vectors, replication-competent, replication-deficient
Abstract: The mucosal surfaces of the respiratory, gastrointestinal, and genitourinary tract are entry points for a variety of pathogens and they serve as the first line of defense against infection. To prevent transmission of mucosal pathogens, it is often necessary to target the vaccine to the mucosal surface. Viral vectors, such as poxviruses expressing gene inserts, capable of overcoming the formidable array of host defenses at the mucosal surfaces, are an attractive vaccination strategy for mucosal immunization against infectious diseases. Replication-competent vectors, such as vaccinia, are highly effective, but have a number of safety concerns that may limit their widespread use in humans. In contrast, replication-deficient vectors, such as modified vaccinia ankara (MVA), ALVAC, and NYVAC, may be safer vectors than live vectors, but these vectors may not be as effective at inducing immune responses. Co-delivery of viral vectors with genetic adjuvants (cytokines) or deletion of certain immunomodulatory genomic sequences from these viral vectors may increase vaccine efficiency and are promising strategies for a new generation of mucosal vaccines.
Export Options
About this article
Cite this article as:
Lukena U. Karkhanis and Ted M. Ross , Mucosal Vaccine Vectors: Replication-Competent Versus Replication-Deficient Poxviruses, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039832
DOI https://dx.doi.org/10.2174/138161207781039832 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets 5q- syndrome
Current Pharmaceutical Design An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Current Ocular Drug Delivery Challenges for N-acetylcarnosine: Novel Patented Routes and Modes of Delivery, Design for Enhancement of Therapeutic Activity and Drug Delivery Relationships
Recent Patents on Drug Delivery & Formulation TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects
Mini-Reviews in Medicinal Chemistry Dietary Toxins, Endoplasmic Reticulum (ER) Stress and Diabetes
Current Diabetes Reviews Microbial Antigenic Pressure and Evolution of the Immune Response: Toward a Better Understanding of the Human Immune System in Health and Disease and Therapeutic Interventions
Endocrine, Metabolic & Immune Disorders - Drug Targets ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry